Table 1 The characteristics of the included patients stratified by monitoring status
From: Accuracy of time to treatment estimates in the CRASH-3 clinical trial: impact on the trial results
Monitored | Unmonitored | |
|---|---|---|
(n = 456) | (n = 7651) | |
Received TXA | 229 (50%) | 3852 (50%) |
Head injury death | 186 (41%) | 351 (5%) |
Time to treatment | ||
Mean (SD) | 156 min (86 min) | 178 min (108 min) |
≤ 1 | 51 (11%) | 955 (12%) |
1–2 | 128 (28%) | 2242 (29%) |
2–3 | 185 (41%) | 2117 (28%) |
3–4 | 36 (8%) | 705 (9%) |
4–5 | 18 (4%) | 572 (7%) |
5–6 | 21 (5%) | 500 (7%) |
6–7 | 10 (2%) | 375 (5%) |
7–8 | 7 (2%) | 185 (2%) |
Sex | ||
Male | 368 (81%) | 5937 (78%) |
Female | 88 (19%) | 1713 (22%) |
Unknown | 0 (0%) | 1 (0%) |
GCS | ||
Moderate 9–12 | 297 (65%) | 3535 (46%) |
Mild 13–15 | 159 (35%) | 4051 (53%) |
Unknown | 0 (0%) | 65 (1%) |
SBP (mmHg) | ||
0–89 | 7 (2%) | 57 (1%) |
90–119 | 94 (21%) | 2546 (33%) |
120–139 | 166 (36%) | 2730 (36%) |
140+ | 189 (41%) | 2300 (30%) |
Unknown | 0 (0%) | 18 (0%) |
Age (years) | ||
Mean (SD) | 51 (22) | 43 (20) |
0–15 | 0 (0%) | 2 (0%) |
16–24 | 62 (14%) | 1628 (21%) |
25–34 | 79 (17%) | 1566 (20%) |
35–44 | 42 (9%) | 1172 (15%) |
45–54 | 67 (15%) | 1082 (14%) |
55+ | 206 (45%) | 2201 (29%) |